Clinical Trial

Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Study acronym: HELIOS
Recruiting
View on ClinicalTrials.gov →
Summary
This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-20.
Trial Details
NCT Number NCT07723261
Lead Sponsor Hellenic Cooperative Oncology Group
Conditions Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 70 participants
Start Date 2026-03-30
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-24